RezoluteRZLT
RZLT
About: Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
Employees: 59
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 10
58% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 12
13% more funds holding
Funds holding: 52 [Q2] → 59 (+7) [Q3]
2% more capital invested
Capital invested by funds: $185M [Q2] → $189M (+$3.98M) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
13.26% less ownership
Funds ownership: 83.51% [Q2] → 70.25% (-13.26%) [Q3]
66% less call options, than puts
Call options by funds: $41K | Put options by funds: $119K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
172%
upside
Avg. target
$13
195%
upside
High target
$14
217%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Douglas Tsao 41% 1-year accuracy 68 / 167 met price target | 217%upside $14 | Buy Reiterated | 8 Nov 2024 |
Wedbush Yun Zhong 25% 1-year accuracy 1 / 4 met price target | 172%upside $12 | Outperform Initiated | 5 Nov 2024 |
Financial journalist opinion
Based on 4 articles about RZLT published over the past 30 days
Positive
Zacks Investment Research
1 day ago
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025.
Neutral
GlobeNewsWire
2 weeks ago
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced that its compensation committee has approved the issuance of One Hundred and Fifty Thousand (150,000) shares of its common stock as an inducement award (the “Inducement Award”) permitted under Nasdaq Rule 5635(c)(4) to its new Senior Vice President of Global Product Supply. The Inducement Award was granted on November 30, 2024 and was priced at our closing price on November 29, 2024. The Inducement Award will vest 25% one year after the executive's start date and will vest monthly for 36 months after.
Positive
Zacks Investment Research
3 weeks ago
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug
The FDA bestows an Orphan Drug status to Rezolute's ersodetug for treating hypoglycemia due to tumor hyperinsulinism. Shares rise.
Neutral
Seeking Alpha
3 weeks ago
Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market
Rezolute, Inc. expects to report top-line results from the phase 3 sunRIZE study using ersodetug + placebo to treat patients with Congenital Hyperinsulinism in the 2nd half of 2025. The global Congenital Hyperinsulinism treatment market is estimated to be worth $327.8 million by 2032; the Company believes that cHI and tHI could both generate sales >$1 billion. A phase 3 registrational study, using ersodetug for patients with Tumor Hyperinsulinism expected to start in the 1st half of 2025 and release top-line data from it 2nd half of 2026.
Neutral
GlobeNewsWire
3 months ago
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S.
Neutral
Zacks Investment Research
3 months ago
RZLT Stock Up as FDA Lifts Clinical Holds on Rare Disease Study
The FDA removes the partial clinical holds on Rezolute's phase III study evaluating RZ358 for treating congenital hyperinsulinism.
Positive
Benzinga
3 months ago
FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment
Monday, the FDA removed partial clinical holds on Rezolute, Inc.'s RZLT RZ358 (ersodetug), a potential treatment for hypoglycemia (low blood sugar) caused by congenital hyperinsulinism (HI).
Positive
Reuters
3 months ago
US FDA lifts partial clinical hold on Rezolute's blood sugar treatment
Rezolute Inc said on Monday the U.S. Food and Drug Administration has removed the partial clinical hold on its late-stage study testing its experimental treatment for low blood sugar.
Neutral
GlobeNewsWire
3 months ago
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025 Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025
Neutral
GlobeNewsWire
4 months ago
Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Second rare disease program with RZ358 in Phase 3 development Follows successful treatment of multiple patients with tumor hyperinsulinism under the Company's Expanded Access Program REDWOOD CITY, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that it received U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application for RZ358 (ersodetug) to treat hypoglycemia in patients with tumor hyperinsulinism (HI).
Charts implemented using Lightweight Charts™